In some studies conducted in Europe, diarrhoea is estimated to account for 5-24% of overall pre-weaning mortality and to reduce average daily gain (ADG) by 8-14 g per day. Based on these effects, the cost of neonatal diarrhoea was recently estimated to be 134 € per sow per year. The aim of this study was to assess the financial impact of SUISENG® vaccination under field conditions on a commercial farm located in Portugal.
Economic benefit of vaccination with SUISENG®
Publications
Swine
Appeared in
IPVS Congress, 2013
The economic benefit of vaccination with SUISENG® was demonstrated, not only because of the cost of losses caused by neonatal diarrhoea, but also because of the increased cost resulting from antibiotic treatment of animals in the non-vaccinated groups. The cost at the end of lactation was therefore reduced and the efficacy of vaccination with SUISENG® was demonstrated.
Download this article
Related products
The first intradermal needle-free vaccine against Mycoplasma hyopneumoniae and PCV2, all in one, in suspension for injection
Live vaccine against porcine reproductive and respiratory syndrome (PRRS), in injectable freeze-dried tablet
Purified recombinant verotoxin 2e against edema disease, in suspension for injection
Inactivated vaccine, against progressive and non progressive swine atrophic rhinitis, in injectable suspension.
Inactivated vaccine against neonatal colibacillosis and Clostridium infections in swine, in injectable suspension
Inactivated vaccine against Clostridioides difficile and Clostridium perfringens type A infections in swine, in injectable suspension.
Inactivated vaccine against porcine parvovirus and swine erysipelas, in injectable suspension
Inactivated vaccine against swine erysipelas, parvovirosis and leptospirosis, in injectable suspension
Live vaccine against Aujeszky’s disease gE negative strain, in injectable freeze-dried tablet
Inactivated vaccine against swine erysipelas, in injectable suspension
Inactivated porcine against porcine parvovirus, in injectable suspension
Inactivated vaccine against enzootic pneumonia, in injectable suspension
Related services
Smart Vaccination by HIPRA is a revolutionary concept that combines: A smart vaccine including RFID technology in its label, a vaccination device which ensures precision and efficiency, and a new world of digital solutions in HIPRAlink Vaccination. All these elements are developed internally by HIPRA.
In Swine, the HIPRA SMART VACCINATION is spearheaded by our innovative MHYOSPHERE® PCV ID and UNISTRAIN® PRRS vaccines, the needle-free intradermal device Hipradermic® and the professional veterinary app HIPRAlink® Vaccination.
An innovative service based on data analysis that facilitates decision-making in swine
HIPRA Stats is a data analysis service for animal production companies.
Hipradermic® is an advanced needle-free injection device with wireless connectivity for the intradermal vaccination of pigs.
HIPRA University offers high quality training programmes in strategic areas of interest for professionals
Access an advanced diagnostic service with maximum comfort and reliability
